Table 1 Planned clinical trials of iPS cell-based therapies
From: iPS cell technologies: significance and applications to CNS regeneration and disease
Principal investigator (Institute/Location) | Cell type to transplant | Target disorders |
|---|---|---|
Masayo Takahashi, (RIKEN) | Retinal Pigment Epithelium (sheet) | Age-related macular degeneration (wet type) |
Alfred Lane, Anthony Oro, Marius Wernig (Stanford University) | Keratinocytes | Recessive dystrophic epidermolysis bullosa (RDEB) |
Mahendra Rao (NIH) | DA neurons | Parkinson’s disease |
Koji Eto (Kyoto University) | Megakaryocyte | Thrombocytopenia |
Jun Takahashi (Kyoto University) | DA neurons | Parkinson’s disease |
Steve Goldman, (University of Rochester) | Oligodendrocyte precursor cell | Multiple Sclerosis |
Hideyuki Okano, Masaya Nakamura (Keio University) | Neural stem/progenitor cells | Spinal Cord Injury |
Shigeto Shimmura (Keio University) | Corneal endothelial cells | Corneal endothelial dysfunction |
Koji Nishida (Osaka University) | Corneal epithelial cells (sheet) | Corneal epithelial dysfunction and trauma (e.g. Stevens–Johnson syndrome) |
Yoshiki Sawa (Osaka University) | Cardiomyocytes (sheet) | Heart Failure |
Keiichi Fukuda (Keio University) | Cardiomyocytes (sphere) | Heart Failure |
Yoshiki Sasai and Masayo Takahashi (RIKEN) | Neuroretinal sheet including photoreceptor cells | Retinitis pigmentosa |
Advanced Cell Technology | Megakaryocytes | Refractory thrombocytopenia |